Advertisement

ADVERTISEMENT

Lung Cancer

Brigatinib Plus LCT Safe, Feasible for TKI-Naïve Patients With ALK+ NSCLC
Videos
Brigatinib Plus LCT Safe, Feasible for TKI-Naïve Patients With ALK+ NSCLC
05/31/2020
Yasir Elamin, MD, talks about the findings of a study in which LCT plus brigatinib was shown to be an effective treatment for ALK-rearranged advanced NSCLC.
Yasir Elamin, MD, talks about the findings of a study in which LCT plus brigatinib was shown to be an effective treatment for ALK-rearranged advanced NSCLC.
Yasir Elamin, MD, talks about...
05/31/2020
Oncology
Experts Identify Mutational Biomarker for Poor Prognosis in ALK+ NSCLC
Videos
Experts Identify Mutational Biomarker for Poor Prognosis in ALK+ NSCLC
05/30/2020
David Carbone, MD, PhD, comments on a study in which a mutation was identified as a biomarker for poor prognosis in patients with ALK-positive NSCLC.
David Carbone, MD, PhD, comments on a study in which a mutation was identified as a biomarker for poor prognosis in patients with ALK-positive NSCLC.
David Carbone, MD, PhD, comments...
05/30/2020
Oncology
Combining LCT and Brigatinib May Benefit Patients With ALK+ NSCLC
Videos
Combining LCT and Brigatinib May Benefit Patients With ALK+ NSCLC
05/27/2020
David Carbone, MD, PhD, comments on a study evaluating the use of LCT plus brigatinib for patients with ALK-positive NSCLC.
David Carbone, MD, PhD, comments on a study evaluating the use of LCT plus brigatinib for patients with ALK-positive NSCLC.
David Carbone, MD, PhD, comments...
05/27/2020
Oncology
News
EZH2-Inhibitor Shows Activity in Relapsed/Refractory Malignant Mesothelioma
05/27/2020
Phase 2 trial data demonstrate the antitumor activity of tazemetostat in patients with BAP1-deficient relapsed or refractory malignant mesothelioma.
Phase 2 trial data demonstrate the antitumor activity of tazemetostat in patients with BAP1-deficient relapsed or refractory malignant mesothelioma.
Phase 2 trial data demonstrate...
05/27/2020
Oncology
Pembrolizumab Added to Chemo Maintains OS, PFS Benefits in Metastatic NSCLC
Videos
Pembrolizumab Added to Chemo Maintains OS, PFS Benefits in Metastatic NSCLC
05/27/2020
Yasir Elamin, MD, discusses the clinical significance of the KEYNOTE-189 clinical trial evaluating the use of chemo plus pembrolizumab for metastatic, nonsquamous NSCLC.
Yasir Elamin, MD, discusses the clinical significance of the KEYNOTE-189 clinical trial evaluating the use of chemo plus pembrolizumab for metastatic, nonsquamous NSCLC.
Yasir Elamin, MD, discusses the...
05/27/2020
Oncology
Videos
Fadi Braiteh, MD, Discusses the Ins and Outs of Entrectinib Therapy for NSCLC
12/03/2019
Dr Braiteh spoke in detail about the use of entrectinib therapy in patients with NSCLC at the 2019 Perspectives in Thoracic Oncology meeting.
Dr Braiteh spoke in detail about the use of entrectinib therapy in patients with NSCLC at the 2019 Perspectives in Thoracic Oncology meeting.
Dr Braiteh spoke in detail about...
12/03/2019
Oncology
Videos
Second-Line Therapies in the Treatment of NSCLC
12/01/2019
Edward B. Garon, MD, MS, discusses second-line therapies for the treatment of patients with NSCLC.
Edward B. Garon, MD, MS, discusses second-line therapies for the treatment of patients with NSCLC.
Edward B. Garon, MD, MS,...
12/01/2019
Oncology
Videos
Biomarkers for Immunotherapy in NSCLC
11/25/2019
Edward B. Garon, MD, MS, talks about biomarkers for immunotherapy use in patients with NSCLC.
Edward B. Garon, MD, MS, talks about biomarkers for immunotherapy use in patients with NSCLC.
Edward B. Garon, MD, MS, talks...
11/25/2019
Oncology
Videos
Joshua Bauml, MD, Discusses the Use of Brigatinib Therapy for ALK-Positive NSCLC
11/24/2019
Dr Bauml talks about the use of brigatinib in the treatment of patients with ALK-positive NSCLC.
Dr Bauml talks about the use of brigatinib in the treatment of patients with ALK-positive NSCLC.
Dr Bauml talks about the use of...
11/24/2019
Oncology
Videos
Puneeth Iyengar, MD, PhD, Talks Pros and Cons of Proton Therapy for Stage III NSCLC
11/24/2019
Dr Iyengar discusses the pros and cons of using proton therapy in the management of patients with stage III NSCLC.
Dr Iyengar discusses the pros and cons of using proton therapy in the management of patients with stage III NSCLC.
Dr Iyengar discusses the pros...
11/24/2019
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

December 4 ⁠–⁠ December 5
Great Debates & Updates in Diabetic Foot
December 6 ⁠–⁠ December 7
AIBD logo
December 9 ⁠–⁠ December 11
December 9 ⁠–⁠ December 11
Psych Congress Primary Care Online Series
December 12 ⁠–⁠ December 13
December 14 ⁠–⁠ December 15
February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use